June 23, 2023

Someit Sidhu, M.D. Chief Executive Officer Zura Bio Limited 4225 Executive Square, Suite 600 La Jolla, CA 92037

Re: Zura Bio Limited Registration

Statement on Form S-1

Filed June 14, 2023 File No. 333-272628

Dear Someit Sidhu:

We have limited our review of your registration statement to those issues we have

addressed in our comments. In some of our comments, we may ask you to provide us with

information so we may better understand your disclosure.

 $\,\,$ Please respond to this letter by amending your registration statement and providing the

requested information. If you do not believe our comments apply to your facts and

circumstances or do not believe an amendment is appropriate, please tell us why in your $% \left(1\right) =\left(1\right) \left(1\right)$

response.

 $\qquad \qquad \text{After reviewing any amendment to your registration statement and the information you} \\$

provide in response to these comments, we may have additional comments.

Registration Statement on Form S-1

Cover Page

1. For each of the shares and warrants being registered for resale, disclose the price that the selling securityholders paid for such shares and warrants.

2. Disclose the exercise prices of the warrants compared to the market prices of the underlying securities. If the warrants are out of the money, please disclose the likelihood that warrant holders will not exercise their warrants. Provide similar disclosure in the prospectus summary, risk factors, MD&A and use of proceeds section and disclose that cash proceeds associated with the exercises of the warrants are dependent on the stock price. As applicable, describe the impact on your liquidity and update the discussion on the ability of your company to fund your operations on a prospective basis with your current cash on hand.

Someit Sidhu, M.D.

FirstName LastNameSomeit Sidhu, M.D.

Zura Bio Limited

Comapany

June

NameZura Bio Limited

23, 2023

June 23,

Page 2 2023 Page 2

FirstName LastName

3. We note the significant number of redemptions of your Class A Ordinary Shares in $\ensuremath{\mathsf{Shares}}$

connection with your business combination and that the shares being registered for resale $% \left(1\right) =\left(1\right) +\left(1\right) +$

will constitute a considerable percentage of your public float. If any of the shares being

registered for resale were purchased by the selling securityholders for prices considerably $\ensuremath{\mathsf{S}}$

below the current market price of the Class A Ordinary Shares,

highlight the significant

negative impact sales of shares on this registration statement could have on the public

trading price of the Class A Ordinary Shares.

Risk Factors, page 18

Include an additional risk factor highlighting the negative pressure potential sales of

shares pursuant to this registration statement could have on the public trading price of the

Class A Ordinary Shares. To illustrate this risk, disclose the purchase price of the

securities being registered for resale and the percentage that these shares currently

represent of the total number of shares outstanding. If appropriate, also disclose that, even

if the current trading price returns to or drops below the SPAC IPO price, the private

investors have an incentive to sell because they will still profit on sales because of the

lower price that they purchased their shares than the public investors.

Your cover page references a risk factor entitled "Future resales, or the perception of

future resales, of Class A Ordinary Shares, including the Registrable Shares offered for

resale hereunder, may cause the market price of the Class A Ordinary Shares to decline

significantly, even if our business is doing well. Please revise to include this risk factor.

Rusiness

Overview, page 78

In light of the significant number of redemptions, expand your discussion of capital

resources to address any changes in the company s liquidity position since the business

combination. If the company is likely to have to seek additional capital, discuss the effect

of this offering on the company s ability to raise additional capital.

Please expand your discussion here to reflect the fact that this offering involves the

potential sale of a substantial portion of shares for resale and discuss how such sales could

impact the market price of the company s common stock. Your discussion should

highlight the fact that many of the beneficial owners of your outstanding shares will be

able to sell all of their shares for so long as the registration statement of which this

prospectus forms a part is available for use.

General

Revise your prospectus to disclose the price that each selling securityholder paid for the

shares and warrants being registered for resale. Highlight any differences in the current

trading price, the prices that the Sponsor, private placement investors, PIPE investors, or

other selling securityholders acquired their shares and warrants, and the price that the

public securityholders acquired their shares and warrants. Disclose that while the

Someit Sidhu, M.D.

Zura Bio Limited

June 23, 2023

Page 3

sponsor, private placement investors, PIPE investors, or other selling securityholders may

experience a positive rate of return based on the current trading price, the public

securityholders may not experience a similar rate of return on the securities they

purchased due to differences in the purchase prices and the current trading price. Please

also disclose the potential profit the selling securityholders will earn based on the current

trading price. Lastly, please include appropriate risk factor disclosure. We remind you that the company and its management are responsible for

the accuracy

and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.

Please contact Dillon Hagius at 202-551-7967 or Tim Buchmiller at 202-551-3635 with any questions.

Sincerely,

FirstName LastNameSomeit Sidhu, M.D.

Division of

Corporation Finance Comapany NameZura Bio Limited

Office of Life

Sciences
June 23, 2023 Page 3
cc: Giovanni Caruso, Esq.

FirstName LastName